Post Myocardial Infarction

Monitoring guidance......Page 193
nicecg48_appendices.pdf......Page 0
Appendices......Page 232
Appendix A – Scope......Page 233
Groups that will not be covered......Page 237
Areas that will be covered......Page 238
Guideline......Page 241
1.1.1 Introduction......Page 244
1.1.2 Methods......Page 246
Table 1 Probabilities for a 65-year-old man without Cardiac rehabilitation......Page 249
1.1.3 Results......Page 258
1.1.4 Limitations of the model......Page 267
1.1.5  Conclusions......Page 268
1.1.6 ADDITIONAL INFORMATION: SENSITIVITY ANALYSIS......Page 269
1.2.1 Methods......Page 276
1.2.1.1 Baseline risks:......Page 280
1.2.1.2 Cost effectiveness......Page 284
1.2.2 Results......Page 285
1.2.3 Limitations of the model......Page 289
1.2.4 Conclusions......Page 290
1.2.5 ADDITIONAL INFORMATION: SENSITIVITY ANALYSIS......Page 291
1.3.1 Methods......Page 295
1.3.1.1 Baseline risks:......Page 297
1.3.1.2 Quality of life (Utility):......Page 300
1.3.2 Results......Page 302
1.3.3 Limitations of the model......Page 307
1.3.4 Conclusions......Page 308
1.3.5 Addaitional information: Sensitivity analysis......Page 309
1.4.1 Introduction......Page 314
1.4.2 Clinical evidence......Page 315
1.4.3 Cost-effectiveness evidence......Page 316
1.4.5 Methods for economic analysis......Page 318
Estimation of costs and effects......Page 322
Sensitivity Analysis......Page 325
1.4.7 Discussion......Page 337
1.4.8 Conclusions......Page 339
 Finally, the validity of this analysis depends on acceptance of the proposition that the benefits of omega 3 are confined to people with a recent MI.  We only included effectiveness data from the two trials in this population (DART1 and GISSI-P).  If we were to broaden this evidence base to include the DART2 trial in angina patients, omega-3 supplementation would not appear to be effective or cost-effective.......Page 341
Appendix C –  Clinical Evidence Extractions......Page 347
Ref ID: 21......Page 525
Ref ID: 2919......Page 526
Ref ID: 280......Page 528
Ref ID: 297......Page 529
Ref ID: 166......Page 530
Appendix E - Clinical Questions and Search Strategy......Page 618
Guidelines sources searched......Page 623
1.5 Drug therapy......Page 630
1.5.1 Coronary revascularisation......Page 656
1.6 Lifestyle......Page 658
1.7 Cardiac Rehabilitation......Page 668
1.7.1 Patient Engagement......Page 675
1.7.2 Education & Information......Page 677
1.7.3 Psychological support......Page 680
1.7.4 Sexual activity......Page 683
Appendix F – National Service Framework for Coronary Heart Disease definition of phases of comprehensive cardiac rehabilitation......Page 686
Appendix G – Omega-3 fatty acids content of various oily fish required to provide approximately 1 g of EPA plus DHA per day......Page 688